Search results for "PCS"

showing 10 items of 94 documents

Initial Surface Film on Magnesium Metal. A Characterization by X-ray Photoelectron Spectroscopy (XPS) and Photocurrent Spectroscopy (PCS)

2007

Abstract A detailed investigation of the initial film grown on mechanically polished Mg electrodes has been carried out by ex situ X-ray Photoelectron Spectroscopy (XPS) and in situ Photocurrent Spectroscopy (PCS), allowing to reach a detailed picture of the passive layer structure. The XPS data show that the films formed soon after mechanical treatment and immersion in aqueous electrolyte have a bilayer structure, consisting of an ultra-thin MgO inner layer (∼2.5 nm) and a Mg(OH) 2 external layer. The thickness of the Mg(OH) 2 layer is a function of immersion time and solution temperature. After mechanical treatment and immersion in aqueous solution at room temperature, the MgO/Mg(OH) 2 la…

PhotocurrentChemistryBand gapGeneral Chemical Engineeringcorrosion filmsFermi levelAnalytical chemistryElectrolytemagnesiummagnesium; magnesium hydroxide; XPS; PCS; corrosion filmssymbols.namesakeSettore ING-IND/23 - Chimica Fisica ApplicataX-ray photoelectron spectroscopyPCSElectrochemistrysymbolsXPSSurface layerSpectroscopyLayer (electronics)magnesium hydroxide
researchProduct

Growth and Characterization of Anodic Films on Al-Nb Alloys

2006

Abstract The anodizing behaviours of sputtering-deposited aluminium, niobium and Al-Nb alloys, containing 0.4, 7.5, 21, 40 and 55 at.% niobium, have been examined in 0.1 M ammonium pentaborate electrolyte with interest in the morphology, structure and electronic properties of the anodic oxides. Transmission electron microscopy revealed amorphous oxides, containing units of Nb2O5 and Al2O3, with formation ratios intermediate between those of anodic alumina and anodic niobia. Photocurrent spectroscopy provided increased understanding of the electronic properties of the anodic films, suggesting the formation of “mixed oxides” with insulating behaviours. The estimated band gap values are correl…

PhotocurrentMaterials scienceAnodizingBand gapMetallurgyNiobiumchemistry.chemical_elementPCS TEMElectrolyteAmorphous solidChemical engineeringchemistryAluminiumTransmission electron microscopy
researchProduct

Modelling leaky photonic wires: a mode solver comparison

2006

We present results from a mode solver comparison held within the framework of the European COST P11 project. The structure modelled is a high-index contrast photonic wire in silicon-oninsulator subject to substrate leakage. The methods compared are both in-house developed and commercial, and range from effective index and perturbation methods, over finite-element and finite-difference codes, beam propagation methods, to film mode matching methods and plane wave expansion methods.

Plane waveSubstrate leakageno keywordsIR-67031METIS-248208OpticsBeam propagation methodBoundary value problemElectrical and Electronic EngineeringOptical mode solvers Photonic wires Substrate leakage WaveguidesLeakage (electronics)Physicsbusiness.industryOptical mode solversSolverPhotonic wiresIOMS-PCS: PHOTONIC CRYSTAL STRUCTURESAtomic and Molecular Physics and OpticsFinite element methodElectronic Optical and Magnetic MaterialsEWI-9572IOMS-SNS: SENSORSPlane wave expansionPhotonicsbusinessWaveguides
researchProduct

Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.

2006

Patients homozygous or Compound heterozygous for LDLR mutations or double heterozygous for LDLR and apo B R3500Q mutation have higher LDL-C levels. more extensive xanthomatosis and more severe premature coronary disease (pCAD) than simple heterozygotes for mutations in either these genes or for missense mutations in PCSK9 gene. It is not known whether combined mutations in LDLR and PKCS9 are associated with such a severe phenotype. We sequenced Apo B and PCSK9 genes in two patients with the clinical diagnosis of homozygous FH who were heterozygous for LDLR gene mutations. Proband Z.P. (LDL-C 13.39 mmol/L and pCAD) was heterozygous for an LDLR mutation (p.E228K) inherited from her father (LD…

ProbandLDLR geneAdultMaleSettore MED/09 - Medicina InternaApolipoprotein BFamilial hypercholesterolemia (FH); Autosomal dominant hypercholesterolemia 3 (ADH3); LDLR gene; PCSK9 gene; Premature coronary artery diseasePremature coronary artery diseaseLDLR PCSK9Mutation MissenseFamilial hypercholesterolemiaCompound heterozygositymedicine.disease_causeHyperlipoproteinemia Type IIFamilial hypercholesterolemia (FH) Autosomal dominant hypercholesterolemia 3 (ADH3) LDLR gene PCSK9 gene Premature coronary artery diseaseFamilial hypercholesterolemia (FH)medicineMissense mutationHumansCells CulturedGeneticsMutationbiologybusiness.industrySerine EndopeptidasesHeterozygote advantageMiddle Agedmedicine.diseaseAutosomal dominant hypercholesterolemia 3 (ADH3)PedigreePhenotypeSettore MED/03 - Genetica MedicaAmino Acid SubstitutionReceptors LDLPCSK9 geneLDL receptorbiology.proteinlipids (amino acids peptides and proteins)FemaleProprotein ConvertasesProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessAtherosclerosis
researchProduct

Novel therapeutical approaches to managing atherosclerotic risk

2021

Atherosclerosis is a multifactorial vascular disease that leads to inflammation and stiffening of the arteries and decreases their elasticity due to the accumulation of calcium, small dense Low Density Lipoproteins (sdLDL), inflammatory cells, and fibrotic material. A review of studies pertaining to cardiometabolic risk factors, lipids alterations, hypolipidemic agents, nutraceuticals, hypoglycaemic drugs, atherosclerosis, endothelial dysfunction, and inflammation was performed. There are several therapeutic strategies including Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors, inclisiran, bempedoic acid, Glucagon-Like Peptide-1 Receptor agonists (GLP-1 RAs), and nutraceuticals t…

QH301-705.5InflammationReview030204 cardiovascular system & hematologyPharmacologyCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineLipid oxidationmedicineAnimalsHumans030212 general & internal medicineMolecular Targeted TherapyPhysical and Theoretical ChemistryEndothelial dysfunctionBiology (General)Molecular BiologyQD1-999SpectroscopyInnovative therapiesMolecular signalingVascular diseasebusiness.industryPCSK9Organic ChemistryGeneral MedicineProprotein convertasemedicine.diseaseAtherosclerosisComputer Science ApplicationsManagementChemistryInflammationsAtheromaOxidative stressHypolipidemic Agentslipids (amino acids peptides and proteins)Nutraceuticalsmedicine.symptombusiness
researchProduct

Factors affecting the amount and the mode of merocyanine 540 binding to the membrane of human erythrocytes. A comparison with the binding to leukemia…

1995

Abstract In the presence of albumin Merocyanine 540 (MC540) exhibits a very limited binding to the outer surface of the membrane of normal erythrocytes, whereas pronounced binding is observed to leukemia cells. To find out whether this difference is due to differences in the composition or structural organization of the cell membrane we analyzed effects of a number of covalent and non-covalent perturbations of the red cell membrane on the binding and fluorescence characteristics of membrane-bound MC540. It is shown that exposure of the cells to cationic chlorpromazine, neuraminidase or photodynamic treatment with AlPcS 4 as sensitizer caused a limited increase (30–50%) of MC540 binding, tog…

Radiation-Sensitizing AgentsTMA-DPHHot TemperatureIndolesBSALightChlorpromazineLipid BilayersBiophysicsPhospholipidNeuraminidaseQuantum yieldPyrimidinonesBiochemistryCell membranechemistry.chemical_compoundt-BuOOHOrganometallic CompoundsTumor Cells CulturedmedicineMerocyanine 540HumansPBSCell MembraneErythrocyte MembraneMembrane structureCell Biologymedicine.diseasePEGFluorescenceDIDSLeukemiaLeukemia cellAlPcS4CholesterolSpectrometry FluorescenceMembranemedicine.anatomical_structureBNML cellsBiochemistrychemistryLeukemia MyeloidCovalent bondBiophysicsMC540Biochimica et Biophysica Acta (BBA) - Biomembranes
researchProduct

Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de …

2021

Different primary and secondary prevention studies have documented that a greater degree of reduction in low-density lipoprotein cholesterol (LDL-C) levels is associated with a greater decrease in cardiovascular event rates. PCSK9 inhibitors achieve important, rapid and sustained decreases in LDL-C. New clinical practice guidelines for the management of dyslipidemia establish reduced target levels of LDL-C. These goals are hardly achievable with a statin-only treatment, even in combination with ezetimibe. The addition of PCSK9 inhibitors can play a determining role in achieving these recommendations. However, it is important to identify the patient subgroups that can most benefit from this …

Secondary preventionGynecologyCardiovascular eventmedicine.medical_specialtybusiness.industryPatient subgroupsmedicine.diseaseClinical PracticeEzetimibemedicinelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessPCSK9 InhibitorsDyslipidemiaLipoprotein cholesterolmedicine.drugREC: CardioClinics
researchProduct

Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidis…

2020

High levels of LDL cholesterol (LDL-C) represent a causal factor for cardiovascular diseases on an atherosclerotic basis, with a direct correlation between these and mortality or cardiovascular events, such that the reduction of both is associated proportionally and linearly with the reduction of LDL-C.Statins and ezetimibe are used for LDL-C lowering but may not be sufficient to achieve the targets defined by the ESC/EAS guidelines, which recommend use of PCSK9 inhibitors for further LDL-C reduction in patients not at goal.This project submitted 86 clinical scenarios to a group of experts, cardiologists, internists and lipidologists, collecting their opinion on the appropriateness of diffe…

Settore MED/09 - Medicina InternaConsensusPCSK9 inhibitorFamilial hypercholesterolemiaHypercholesterolemiaAntibodies Monoclonal Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol LDL; Consensus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Risk Assessment; Risk Factors; Cardiovascular DiseasesConsensuAntibodies Monoclonal HumanizedRisk AssessmentAntibodiesLDLAcute coronary syndrome; Alirocumab; Cardiovascular risk; Familial hypercholesterolemia; PCSK9 inhibitors; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol LDL; Consensus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Risk Assessment; Risk Factors; Cardiovascular DiseasesRisk FactorsAnticholesteremic AgentMonoclonalHumansHumanizedAnticholesteremic AgentsCholesterol LDLCardiovascular riskAtherosclerosisCholesterolItalyPCSK9 inhibitorsCardiovascular DiseasesAtherosclerosiAcute coronary syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsAlirocumab
researchProduct

New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia.

2021

: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder. The most common cause is a mutation in both alleles of the gene encoding for the low-density lipoprotein (LDL) receptor, although other causative mutations have been identified. Complications of atherosclerotic cardiovascular disease are common in these patients; therefore, reducing the elevated LDL-cholesterol burden is critical in their management. Conventionally, this is achieved by patients initiating lipid-lowering therapy, but this can present challenges in clinical practice. Fortunately, novel therapeutic strategies have enabled promising innovations in HoFH treatment. This review highlights recent and ongo…

Settore MED/09 - Medicina InternaGenetic enhancementHomozygous familial hypercholesterolemiaFamilial hypercholesterolemiaInclisiranBioinformaticsmedicine.disease_causeBenzimidazolePCSK9Hyperlipoproteinemia Type IIchemistry.chemical_compoundGene therapyAnticholesteremic AgentmedicineAngiopoietin-like 3HumansLow-density lipoprotein cholesterolAlleleAngiopoietin-like 3; Gene therapy; Gene-editing; Homozygous familial hypercholesterolemia; Inclisiran; Lomitapide; Low-density lipoprotein cholesterol; PCSK9MutationGene-editingAtherosclerotic cardiovascular diseasebusiness.industryPCSK9Anticholesteremic AgentsHomozygoteGenetic disorderGeneral MedicineCholesterol LDLmedicine.diseaseLomitapideLomitapidechemistrylipids (amino acids peptides and proteins)BenzimidazolesCardiology and Cardiovascular MedicinebusinessHumanHeart failure clinics
researchProduct

A novel therapeutic strategy to cure the Homozygous Familial Hypercholesterolemia with residual LDL receptor activity

2020

Settore MED/09 - Medicina InternaLDLR Homozygous Familial Hypercholesterolemia PCSK9 IDOL
researchProduct